Home › Compare › TRKUF vs MRK

TRKUF vs MRK: Dividend Comparison 2026

TRKUF yields 25000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRKUF wins by $481652020747103174656.00M in total portfolio value
10 years
TRKUF
TRKUF
● Live price
25000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$481652020747103174656.00M
Annual income
$477,891,679,681,809,340,000,000,000.00
Full TRKUF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — TRKUF vs MRK

📍 TRKUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRKUFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRKUF + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TRKUF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRKUF
Annual income on $10K today (after 15% tax)
$2,125,000.00/yr
After 10yr DRIP, annual income (after tax)
$406,207,927,729,537,960,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, TRKUF beats the other by $406,207,927,729,537,960,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRKUF + MRK for your $10,000?

TRKUF: 50%MRK: 50%
100% MRK50/50100% TRKUF
Portfolio after 10yr
$240826010373551587328.00M
Annual income
$238,945,839,840,904,670,000,000,000.00/yr
Blended yield
99.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TRKUF
No analyst data
Altman Z
-4.2
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRKUF buys
0
MRK buys
0
No recent congressional trades found for TRKUF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRKUFMRK
Forward yield25000.00% ✓2.76%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7% ✓
Portfolio after 10y$481652020747103174656.00M ✓$56.8K
Annual income after 10y$477,891,679,681,809,340,000,000,000.00 ✓$9,798.13
Total dividends collected$481404327977371041792.00M ✓$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TRKUF vs MRK ($10,000, DRIP)

YearTRKUF PortfolioTRKUF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$2,510,700$2,500,000.00$11,206$366.19+$2.50M → TRKUF
2$589,298,599$586,612,149.53$12,650$502.35+$589.29M → TRKUF
3$129,309,604,119$128,679,054,618.90$14,407$694.19+$129309.59M → TRKUF
4$26,527,150,102,459$26,388,788,826,051.22$16,585$967.82+$26527150.09M → TRKUF
5$5,087,743,001,217,608$5,059,358,950,607,977.00$19,342$1,363.89+$5087743001.20M → TRKUF
6$912,316,496,169,531,500$906,872,611,158,228,600.00$22,913$1,947.19+$912316496169.51M → TRKUF
7$152,954,929,371,424,950,000$151,978,750,720,523,570,000.00$27,662$2,823.89+$152954929371424.91M → TRKUF
8$23,976,822,470,935,107,000,000$23,813,160,696,507,682,000,000.00$34,159$4,173.35+$23976822470935108.00M → TRKUF
9$3,514,337,444,199,857,700,000,000$3,488,682,244,155,957,000,000,000.00$43,337$6,308.80+$3514337444199857664.00M → TRKUF
10$481,652,020,747,103,200,000,000,000$477,891,679,681,809,340,000,000,000.00$56,776$9,798.13+$481652020747103174656.00M → TRKUF

TRKUF vs MRK: Complete Analysis 2026

TRKUF — Stock

Tarku Resources Ltd. engages in the exploration of mineral resources in Quebec and Arizona. The company explores for gold, lead, zinc, silver, copper, manganese, nickel, and platinum group element deposits. It holds 100% interests in the Apollo project covering 96 claims with an area of 5,273 hectares; Admiral project comprising 78 claims with an area of 4,334 hectares; and Atlas project consisting of 74 claims with an area of 4,111 hectares located in Quebec. The company also holds 100% interests in the Richardson project covering 42 mining claims covering 2,319 hectares; and Bullion project comprising 26 mining claims covering 1,435 hectares situated in Chibougamau. Tarku Resources Ltd. is headquartered in Saskatoon, Canada.

Full TRKUF Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this TRKUF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRKUF vs SCHDTRKUF vs JEPITRKUF vs OTRKUF vs KOTRKUF vs MAINTRKUF vs JNJTRKUF vs ABBVTRKUF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.